Stabilitech
iosBio is a biotechnology company focused on developing transformative oral vaccines for major infectious diseases using proprietary platforms. Their lead candidate, OraPro-EBV, targets Epstein-Barr Virus, addressing a significant unmet need linked to multiple sclerosis, mononucleosis, and cancers. The company leverages a combination of advanced technologies including their OraPro™ platform for thermostable, self-administered oral vaccines, Enhanced Surface Display (ESD™) to improve antigen visibility for stronger immune responses, and AI-Assisted Antigen Design to accelerate development. iosBio aims to overcome challenges with traditional vaccines such as cold chain logistics and needle administration, offering improved global accessibility and generating both mucosal and systemic immunity. They are currently seeking £12-30 million in Series B funding to advance OraPro-EBV into Phase 1 clinical trials.
Stabilitech
iosBio is a biotechnology company focused on developing transformative oral vaccines for major infectious diseases using proprietary platforms. Their lead candidate, OraPro-EBV, targets Epstein-Barr Virus, addressing a significant unmet need linked to multiple sclerosis, mononucleosis, and cancers. The company leverages a combination of advanced technologies including their OraPro™ platform for thermostable, self-administered oral vaccines, Enhanced Surface Display (ESD™) to improve antigen visibility for stronger immune responses, and AI-Assisted Antigen Design to accelerate development. iosBio aims to overcome challenges with traditional vaccines such as cold chain logistics and needle administration, offering improved global accessibility and generating both mucosal and systemic immunity. They are currently seeking £12-30 million in Series B funding to advance OraPro-EBV into Phase 1 clinical trials.